Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; and EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, including devices and over-the-counter products for dry eye, over-the-counter products for contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon, Inc. in December 2001. Alcon, Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
IPO Year: 2019
Exchange: NYSE
Website: alcon.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/21/2025 | Overweight → Neutral | Analyst | |
| 5/20/2025 | Buy → Hold | Deutsche Bank | |
| 5/14/2025 | $102.00 → $99.00 | Buy | BTIG Research |
| 3/28/2025 | $107.00 → $110.00 | Buy | Needham |
| 3/25/2025 | Neutral → Buy | BofA Securities | |
| 1/24/2025 | $108.00 → $106.00 | Buy | Needham |
| 1/10/2025 | Neutral → Buy | Redburn Atlantic | |
| 12/17/2024 | $103.00 → $108.00 | Buy | Needham |
| 11/12/2024 | Buy | Needham | |
| 10/10/2024 | Sell → Neutral | Redburn Atlantic |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Analyst downgraded Alcon from Overweight to Neutral
Deutsche Bank downgraded Alcon from Buy to Hold
BTIG Research reiterated coverage of Alcon with a rating of Buy and set a new price target of $99.00 from $102.00 previously
Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $110.00 from $107.00 previously
BofA Securities upgraded Alcon from Neutral to Buy
Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $106.00 from $108.00 previously
Redburn Atlantic upgraded Alcon from Neutral to Buy
Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $108.00 from $103.00 previously
Needham reiterated coverage of Alcon with a rating of Buy
Redburn Atlantic upgraded Alcon from Sell to Neutral
Fastest customizable press release news feed in the world
Raises Concerns About Whether the Board Fulfilled Its Fiduciary Duty of Care in Doubling Down on Its Commitment to Proposed Transaction Renewed Support Comes After Stunning Revelation STAAR CEO and Chair Failed to Disclose Inbound Interest in Acquiring the Company to Rest of Board Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today issued the following letter to the Board of Directors (the "Board") of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Broadwood, which owns 27.5% of STAAR's outstanding common shares, continues to urge its fellow shareholders to vote on its GREEN Proxy Card "AGAINST" the proposed acquisition of STAAR by Alcon Inc. (
Comments on Glass Lewis Report STAAR Surgical Company (NASDAQ:STAA) ("STAAR"), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today provided the following statement in response to a report issued by Glass, Lewis & Co., LLC ("Glass Lewis") related to STAAR's pending merger with Alcon (SIX/NYSE:ALC): The STAAR Board of Directors and management team strongly disagree with the recommendation issued by Glass Lewis. Alcon is paying STAAR stockholders a 59% premium to the 90-day VWAP, whereas Broadwood's proposal to vote down the merger could allow Broadwood to take control without paying any premium to other stockholders.
Glass Lewis Highlights Numerous Concerns Regarding the Sale Process, Timing, and Price Confirms CEO and Chair Did Not Disclose Information to the Rest of the Board About Inbound Interest in Acquiring the Company Finds STAAR Shareholders Would Be Better Served by Rejecting the Proposed Merger Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we") today announced that Glass, Lewis & Co., LLC ("Glass Lewis"), a leading independent proxy advisory firm, has recommended that the shareholders of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) vote "AGAINST" the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE:ALC) on the terms announced on August 5, 2025
Conflicted Management Team Sharply Revised Its Financial Projections Downward Just Days Before Board Vote on Sale to Alcon Continues to Urge STAAR Shareholders to Vote "AGAINST" the Proposed Transaction Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we") today sent the following letter to the shareholders of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Broadwood, which owns 27.5% of STAAR's outstanding common shares, continues to urge its fellow shareholders to vote on its GREEN Proxy Card "AGAINST" the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE:ALC). Shareholders can find additional information at www.LetSTAARShine.com. October 8,
CHARLOTTE, N.C., Oct. 7, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) owning approximately 1.5% of the Company's outstanding common stock, today issued the following statement outlining its opposition of the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE:ALC): We have been significant STAAR shareholders for more than ten years and remain convicted in the significant value of the Company. The proposed sale of STAAR to Alcon for $28 per share significantly undervalues the Company, especially when considering the STAAR Board of Directors' rejection of Alcon's previous offer fo
STAAR Continues to Significantly Underestimate the Strength of the Business and Future Prospects and Misrepresent Its Performance, Competitive Position, and Market Penetration Incentives for STAAR's CEO Are Not Aligned with Shareholders Shareholders Should Preserve the Value of Their Investment and Vote Against the Proposed Merger Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today released the following open letter reiterating its opposition to the proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on A
Contends There Is No Business Justification for the Board's Decision to Sell the Company for $28 Per Share Now After Rejecting $58 Per Share from Alcon Last Year Encourages Shareholders to Vote "AGAINST" the Proposed Acquisition Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today issued the following letter to the Board of Directors (the "Board") of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Broadwood, which owns 27.5% of STAAR's outstanding common shares, continues to urge its fellow shareholders to vote on its GREEN Proxy Card "AGAINST" the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE:ALC). Shareholders can find addition
All STAAR Stockholders Encouraged to Vote "FOR" Alcon Merger on the WHITE Proxy Card STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today highlighted commentary from numerous independent industry analysts who recognize that STAAR's merger with Alcon (SIX/NYSE:ALC) – and the compelling, certain, premium cash value it provides – is the best path forward for STAAR stockholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251005004576/en/ Stephen Farrell, CEO of STAAR, said, "Prior to the Alcon transaction, the median s
Broadwood Believes the Transaction Comes at the Wrong Time, After the Wrong Process, and at the Wrong Price For the Reasons Described in the Presentation, Broadwood Urges All Stockholders to Vote "AGAINST" the Proposed Merger Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood"), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today announced that it has published a presentation outlining why stockholders should vote on Broadwood's GREEN Proxy Card "AGAINST" the proposed acquisition of the Company by an affiliate of Alcon Inc. (NYSE:ALC) on the terms announced on August 5, 2025. The 81-p
Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA) ("STAAR"), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Alcon's acquisition of STAAR, expired at 11:59 p.m. ET on September 29, 2025. As previously announced, under the terms of the agreement, Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR's 90-day volume weighted average price and a 51% premium to the cl
DEFM14A - ALCON INC (0001167379) (Filer)
Live Leadership Updates
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
Live finance-specific insights
Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the US Announced agreement to acquire STAAR Surgical, expanding Alcon's presence in myopia correction Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month
STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d
First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro PF in Q1 2025; Unity VCS and PanOptix Pro in May 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31
Shareholders approve all agenda items presented Deborah Di Sanzo elected as new member of the Board 2024 Compensation Report and Report on Non-Financial Matters approved in advisory votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting ("AGM"). A total of 332,704,408 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,308,176.32, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who stood f
Alcon welcomes its shareholders to its third in-person AGM Alcon Board of Directors proposes to elect Deborah Di Sanzo as a new Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 6, 2025. Alcon is pleased to welcome shareholders to its third in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect Deborah Di Sanzo as a new Board member. An innovative business leader with more than thirty years of experience in the f
Leverages Alcon's global scale with Aurion's cell therapy expertise to accelerate U.S. Phase 3 development in fall of 2025 Aurion's lead asset received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation from the U.S. Food and Drug Administration (FDA) Positions Alcon at the leading edge of biopharma applications in ophthalmology with the potential to advance the first-ever corneal cell therapy candidate Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company developing advanced cell therapies to treat eye d
Full-year 2024 sales of $9.8 billion, up 5%, or up 6% constant currency1 (cc) Full-year 2024 diluted EPS of $2.05, up 5% on a reported basis, or up 11% cc; core diluted EPS2 of $3.05 up 11% on a reported basis, or up 16% cc Generated record $2.1 billion of cash from operations in full-year 2024; record free cash flow3 of $1.6 billion, up 120% Announced share repurchase authorization to offset dilution from associate equity incentive plans Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2024. For the fourth quarter of 2024, sales were $2.5
Third-quarter 2024 sales of $2.4 billion, up 6% on a reported and constant currency1 (cc) basis Third-quarter 2024 diluted EPS of $0.53, up 29%, or 32% cc; core diluted EPS2 of $0.81, up 23%, or 25% cc Generated $1.6 billion of cash from operations in the first nine months of 2024; record free cash flow3 of $1.3 billion, up $704 million, or 119% Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2024. For the third quarter of 2024, sales were $2.4 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarte
Record Q2 2024 sales of $2.5 billion, up 3%, or 6% constant currency1 (cc) Q2 2024 diluted EPS of $0.45, up 32%, or 47% cc; core diluted EPS2 of $0.74, up 7%, or 15% cc H1 2024 cash from operations of $871 million; free cash flow3 of $667 million, up $478 million, or 253% Received U.S. FDA clearance of Unity VCS/CS and PDUFA date for AR-15512 of May 30th, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2024. For the second quarter of 2024, sales were $2.5 billion, an increase of 3% on a reported basis and 6% on a constant currency basis1, as
First-quarter 2024 sales of $2.4 billion, up 5%, or 7% constant currency1 (cc) First-quarter 2024 diluted EPS of $0.50, up 43%, or 62% cc; core diluted EPS2 of $0.78 up 11%, or 21% cc First-quarter 2024 cash from operations of $341 million; free cash flow3 of $229 million, up $248 million year-over year Dividend of CHF 0.24 per share approved by shareholders at the Annual General Meeting on May 8, 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2024. For the first quarter of 2024, sales were $2.4 billion, an increase of 5% on a reported basis and 7% on a consta
This live feed shows all institutional transactions in real time.
SC 13G - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)